Richard Thomas Hoppe MD FASTRO, FACR, FARS, FASCO

Radiation Oncology•Stanford, CA

Professor, Radiation Oncology, Stanford University Medical Center

Join to View Full Profile

875 Blake Wilbur DriveRoom Cc-G228Stanford, CA 94305
Phone+1 650-723-5510
Fax+1 650-498-6922

Summary

Richard Hoppe, MD is a radiation oncologist based in Stanford, CA, specializing in lymphoma. He completed his residency in Radiation Oncology at Stanford Health Care-Sponsored Stanford University after graduating from Weill Cornell Medicine in 1971. Dr. Hoppe has multiple publications in respected medical journals and has been involved in several clinical trials, mostly focusing on lymphoma. He has been recognized for his work with assorted honors and awards including Gold Medals from the American Society for Radiation Oncology, the American College of Radiology, and the American Radium Society, as well as a Lifetime Achievement Award from the International Society for Cutaneous Lymphoma in 2020.

Education & Training

Stanford Health Care-Sponsored Stanford UniversityResidency, Radiation Oncology, 1972 - 1976
Weill Cornell MedicineClass of 1971

Certifications & Licensure

NY State Medical License 1972 - Present
CA State Medical License 1972 - 2028
American Board of Radiology Radiation Oncology

Awards, Honors, & Recognition

Gold Medal American Society for Radiation Oncology (ASTRO
Gold Medal American College of Radiology (ACR)
Gold Medal American Radium Society (ARS)
Janeway Lecture American Radium Society
Lifetime Achievement Award International Society for Cutaneous Lymphoma, 2020
Karl Musshoff Award for Clinical Research German Hodgkin Study Group, 2018
America's Top Doctors Castle Connolly, 2004-2014
America's Top Doctors for Cancer Castle Connolly, 2005-2013
CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013
Join now to see all

Clinical Trials

Rituximab in Treating Patients With Hodgkin's Lymphoma Start of enrollment: 1999 Jan 01
Completed
Phase 2
Autologous Followed by Non-myeloablative Allogeneic Transplantation for Non-Hodgkin's Lymphoma Start of enrollment: 2007 Jan 01
Terminated
Phase 2
Ph II of Non-myeloablative Allogeneic Transplantation Using TLI & ATG In Patients w/ Cutaneous T Cell Lymphoma Start of enrollment: 2009 May 01
Completed
Phase 2
Phase 2 Total Skin Electron Beam Therapy (TSEBT 12 Gy) in Stage IB-IIIA Mycosis Fungoides Start of enrollment: 2009 Jun 01
Terminated
Combined Blood Stem Cell and Kidney Transplant of One Haplotype Match Living Donor Pairs. Start of enrollment: 2010 Jul 14
Active, not recruiting
Phase 1
Brentuximab Vedotin (SGN-35) in Patients With Mycosis Fungoides With Variable CD30 Expression Level Start of enrollment: 2011 May 01
Completed
Phase 2
Immunostimulatory CpG SD-101 + RT in Recurrent/Progressive Lymphoma After Allogeneic Hematopoietic Cell Transplantation (HCT) Start of enrollment: 2012 Aug 01
Terminated
Phase 1
Join now to see all

Publications & Presentations

PubMed

Distinct cell state ecosystems for nodular lymphocyte-predominant Hodgkin lymphoma.
Ajay Subramanian, Shengqin Su, Jamie Flerlage, Stefan Alig, Sheren Younes
Nature Communications. 2025-09-26
An Individualized Prediction Model for Early-Stage Classic Hodgkin's Lymphoma.
Angie Mae Rodday, Andrew M Evens, Matthew J Maurer, Jenica N Upshaw, Nicholas Counsell
NEJM Evidence. 2025-09-01
1 citations
ASTCT and USCLC clinical practice recommendations for allogeneic stem cell transplant in mycosis fungoides and Sézary syndrome.
Amrita Goyal, Daniel O'Leary, Bouthaina Dabaja, Wen-Kai Weng, Jasmine Zain
Journal of the American Academy of Dermatology. 2025-08-01

Abstracts/Posters

A Pilot Study of Brentuximab Vedotin Combined with AVD Chemotherapy and Radiotherapy in Patients with Newly Diagnosed Early Stage, Unfavorable Risk Hodgkin Lymphoma
Richard T Hoppe, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019

Other

Clinical manifestations, pathologic features, and diagnosis of mycosis fungoides
Hoppe RT, Kim YH
http://www.uptodate.com/contents/clinical-manifestations-pathologic-features-and-diagnosis-of-mycosi
UpToDate, Wolters Kluwer Health - 2013-01-28
Staging and prognosis of mycosis fungoides and S??zary syndrome
Hoppe RT, Kim YH
http://www.uptodate.com/contents/staging-and-prognosis-of-mycosis-fungoides-and-sezary-syndrome
UpToDate, Wolters Kluwer Health - 2013-02-22
Treatment of advanced stage (IIB to IV) mycosis fungoides and S??zary syndrome
Hoppe RT, Kim YH
http://www.uptodate.com/contents/treatment-of-advanced-stage-iib-to-iv-mycosis-fungoides-and-sezary-
UpToDate, Wolters Kluwer Health - 2013-02-05
Treatment of early stage (IA to IIA) mycosis fungoides
Hoppe RT, Kim YH
http://www.uptodate.com/contents/treatment-of-early-stage-ia-to-iia-mycosis-fungoides
UpToDate, Wolters Kluwer Health - 2013-03-12
Clinical trials of specific regimens in favorable prognosis early (stage I-II) classical Hodgkin lymphoma
Hoppe RT, Mauch PM
http://www.uptodate.com/contents/clinical-trials-of-specific-regimens-in-favorable-prognosis-early-s
UpToDate, Wolters Kluwer Health - 2012-12-12
Definition of favorable and unfavorable prognosis early (stage I-II) classical Hodgkin lymphoma
Hoppe RT, Mauch PM
http://www.uptodate.com/contents/definition-of-favorable-and-unfavorable-prognosis-early-stage-i-ii-
UpToDate, Wolters Kluwer Health - 2013-03-29
Treatment of favorable prognosis early (stage I-II) classical Hodgkin lymphoma
Hoppe RT, Mauch PM
http://www.uptodate.com/contents/treatment-of-favorable-prognosis-early-stage-i-ii-classical-hodgkin
UpToDate, Wolters Kluwer Health - 2013-03-25
Treatment of unfavorable prognosis early (stage I-II) classical Hodgkin lymphoma
Hoppe RT, Mauch PM
http://www.uptodate.com/contents/treatment-of-unfavorable-prognosis-early-stage-i-ii-classical-hodgk
UpToDate, Wolters Kluwer Health - 2013-02-25
Join now to see all

Press Mentions

Stanford Team Prevents Kidney Transplant Rejection Without DrugsApril 24th, 2002

Grant Support

Management Of Mycosis Fungoides And The Sezary SyndromeNational Cancer Institute1985
Management Of Adults With Unfavorable Non-Hodgkin'S LymphomaNational Cancer Institute1985